Compare SE & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SE | REGN |
|---|---|---|
| Founded | 2009 | 1988 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9B | 68.8B |
| IPO Year | 2017 | 1995 |
| Metric | SE | REGN |
|---|---|---|
| Price | $117.53 | $834.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 25 |
| Target Price | $173.69 | ★ $830.16 |
| AVG Volume (30 Days) | ★ 4.7M | 739.9K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.55% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 18.95 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $32.31 | $12.45 |
| Revenue Next Year | $21.53 | $10.13 |
| P/E Ratio | $49.15 | ★ $43.63 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $77.05 | $541.00 |
| 52 Week High | $199.30 | $844.92 |
| Indicator | SE | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 55.91 | 76.50 |
| Support Level | $80.58 | $732.04 |
| Resistance Level | $131.07 | N/A |
| Average True Range (ATR) | 3.83 | 19.45 |
| MACD | -0.59 | 2.17 |
| Stochastic Oscillator | 35.17 | 87.52 |
Sea started as a gaming business, Garena, but in 2015 expanded into e-commerce. Sea operates Southeast Asia's largest e-commerce company, Shopee, in terms of gross merchandise value. Shopee is a hybrid consumer-to-consumer and business-to-consumer marketplace platform operating in Indonesia, Taiwan, Vietnam, Thailand, Malaysia, the Philippines, and Brazil. For Garena, Free Fire is the key revenue-generating game. Sea's third business, Monee, provides lending, payment, digital banking, and insurance services. As of March 2025, Forrest Li, the founder, chair, and CEO, owned 59.1% of the voting power. Tencent owned 18.5% of issued shares with no voting power.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.